Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | FABP1 | P07148 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22029371 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL22080213 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL31681982 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL22080206 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL31682093 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL22080451 | 1.00 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL24257877 | 0.96 | SLC9A3 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL24257845 | 0.93 | SLC9A3 (0.38) | SLC9A3SMN1; SMN2PKMTDP1 | |
| SCHEMBL22080217 | 0.92 | SLC22A12 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 | |
| SCHEMBL22029404 | 0.92 | SLC22A12 (0.37) | SLC9A3SMN1; SMN2PKMSQSTM1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | SLC9A3 1212/4885SMN1; SMN2 1332/4885PKM 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.